Sugi Predict

Sugi Predict / Targets / MICA

MICA

MHC class I polypeptide-related sequence A (M · Q29983 · MICA on Sugi Atlas →

2,186 patent compounds predicted against MICA, 546 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3919085 SCHEMBL3919085 0.64 16/20
SCHEMBL8235992 SCHEMBL8235992 0.59 16/20
SCHEMBL8235594 SCHEMBL8235594 0.46 13/20
SCHEMBL20743022 SCHEMBL20743022 0.49 11/20
SCHEMBL8227997 SCHEMBL8227997 0.47 11/20
SCHEMBL4488563 SCHEMBL4488563 0.45 11/20
SCHEMBL7745771 SCHEMBL7745771 0.57 9/20
SCHEMBL15388874 SCHEMBL15388874 0.51 9/20
SCHEMBL8232539 SCHEMBL8232539 0.45 9/20
SCHEMBL22048232 SCHEMBL22048232 0.38 9/20
SCHEMBL1307758 SCHEMBL1307758 0.54 8/20
SCHEMBL1309664 SCHEMBL1309664 0.53 8/20
SCHEMBL18705673 SCHEMBL18705673 0.38 8/20
SCHEMBL1308440 SCHEMBL1308440 0.53 7/20
SCHEMBL5106559 SCHEMBL5106559 0.40 7/20
SCHEMBL6850836 SCHEMBL6850836 0.55 6/20
SCHEMBL6706746 SCHEMBL6706746 0.54 6/20
SCHEMBL13485786 SCHEMBL13485786 0.53 6/20
SCHEMBL20665433 SCHEMBL20665433 0.52 6/20
SCHEMBL1350744 SCHEMBL1350744 0.50 6/20

Clinical trials — most relevant to MICA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk PHASE1/PHASE2RECRUITING
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection PHASE1/PHASE2RECRUITING
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood PHASE1/PHASE2COMPLETED
TEIPP Immunotherapy in Patients With NSCLC PHASE1/PHASE2COMPLETED
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma PHASE1/PHASE2COMPLETED
Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer PHASE2COMPLETED
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma PHASE2COMPLETED
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma PHASE2COMPLETED
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers PHASE1/PHASE2UNKNOWN
Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma PHASE2RECRUITING
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant PHASE2COMPLETED
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma PHASE2RECRUITING
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma PHASE1/PHASE2COMPLETED
Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients PHASE2COMPLETED
Consolidation Therapy in Patients With Hematologic Malignancies PHASE1/PHASE2WITHDRAWN
Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors PHASE1UNKNOWN
Exploratory Clinical Study of TCR-T for MAGE-A4-positive Mesenchymal Malignancies PHASE1RECRUITING
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults PHASE1COMPLETED
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma EARLY_PHASE1UNKNOWN
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma. EARLY_PHASE1RECRUITING
Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms EARLY_PHASE1COMPLETED
Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms EARLY_PHASE1UNKNOWN
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers nanRECRUITING
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates nanCOMPLETED
Immunogenetics Predictors With COVID-19 nanUNKNOWN
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome nanCOMPLETED
Comparison of the Severity of Coronary Atherosclerosis With Tissue Compliance in Patients Within First Degree Relatives nanUNKNOWN
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MICA binder may also engage these)

ProteinNameSimilarity
Q29980 — 1.000 Q29980 →
A0A0G2K7V7 — 0.996 A0A0G2K7V7 →
P14432 — 0.996 P14432 →
Q61559 — 0.993 Q61559 →
Q8HWE5 — 0.993 Q8HWE5 →
Q8HWB0 — 0.991 Q8HWB0 →
P13599 — 0.991 P13599 →
P60018 — 0.991 P60018 →
O19477 — 0.990 O19477 →
P13747 — 0.989 P13747 →
Q95460 — 0.988 Q95460 →
Q9GL43 — 0.988 Q9GL43 →
P25311 — 0.987 P25311 →
P30686 — 0.987 P30686 →
Q8HWE7 — 0.987 Q8HWE7 →
Q30201 — 0.987 Q30201 →
Q9GKZ0 — 0.987 Q9GKZ0 →
P30383 — 0.987 P30383 →
Q9BCU3 — 0.987 Q9BCU3 →
P70387 — 0.987 P70387 →
P14427 — 0.987 P14427 →
Q5RD09 — 0.986 Q5RD09 →
Q9BD50 — 0.986 Q9BD50 →
Q2KN22 — 0.986 Q2KN22 →
Q60I18 — 0.986 Q60I18 →
P01901 — 0.985 P01901 →
O35799 — 0.985 O35799 →
P06339 — 0.985 P06339 →
Q13291 — 0.985 Q13291 →
P01902 — 0.985 P01902 →